FrancophonIA/ELRC3.0 huggingface dataset:
English: Further information on Vizimpro can be found on the Agency's website: www.ema.europa.eu/medicines/human/EPAR/vizimpro.
Estonian: Lisateave Vizimpro kohta on ameti veebilehel: www.ema.europa.eu/medicines/human/EPAR/vizimpro.
English: Vizimpro is available as tablets (15, 30 and 45 mg).
Estonian: Seda turustatakse tablettidena (15, 30 ja 45 mg).
English: What measures are being taken to ensure the safe and effective use of Vizimpro?
Estonian: Mis meetmed võetakse, et tagada Vizimpro ohutu ja efektiivne kasutamine?
English: The European Medicines Agency therefore decided that Vizimpro's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Seetõttu otsustas Euroopa Ravimiamet, et Vizimpro kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: The patient should normally take a 45-mg tablet once a day, at around the same time every day, for as long as they benefit from it and the side effects are tolerable.
Estonian: Patsient peaks tavaliselt võtma ühe 45 mg tableti üks kord ööpäevas iga päev ligikaudu samal kellaajal, kuni see on talle kasulik ja kõrvalnähud on talutavad.
English: Other information about Vizimpro
Estonian: Muu teave Vizimpro kohta
English: Before starting treatment, the presence of mutations in the EGFR gene should be confirmed by appropriate tests.
Estonian: Enne ravi alustamist tuleks asjakohaste katsetega kinnitada EGFR-i geeni mutatsioonide olemasolu.
English: Vizimpro (dacomitinib)
Estonian: Vizimpro (dakomitiniib)
English: Vizimpro (dacomitinib) EMA/89209/2019
Estonian: Vizimpro (dakomitiniib) EMA/89209/2019
English: As for all medicines, data on the use of Vizimpro are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Vizimpro kasutamise kohta pidevat järelevalvet.
English: Although Vizimpro caused more side effects than gefitinib, these were considered manageable.
Estonian: Ehkki Vizimprol oli rohkem kõrvalnähte kui gefitiniibil, peeti neid hallatavateks.
English: Side effects reported with Vizimpro are carefully evaluated and any necessary action taken to protect patients.
Estonian: Vizimpro kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: What is Vizimpro and what is it used for?
Estonian: Mis on Vizimpro ja milleks seda kasutatakse?
English: It blocks the activity of EGFR, which normally controls growth and division of cells.
Estonian: See blokeerib EGFR-i aktiivsust, mis normis reguleerib rakkude kasvu ja jagunemist.
English: Vizimpro is used on its own and only in patients with certain mutations (changes) in the gene for a protein called epidermal growth factor receptor (EGFR).
Estonian: Vizimprot kasutatakse ainuravimina ja üksnes patsientidel, kellel esineb teatud mutatsioone (muutusi) geenis, mis kodeerib valku, mida nimetatakse epidermaalse kasvufaktori retseptoriks (EGFR).
English: The most common side effects with Vizimpro (which may affect more than 1 in 5 people) are diarrhoea, rash, stomatitis (inflammation of the lining of the mouth), nail disorder, dry skin, loss of appetite, conjunctivitis (redness and discomfort in the eye), weight and hair loss, itching, elevated levels of transaminases (a sign of liver problems) and nausea (feeling sick).
Estonian: Vizimpro kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 5st) on kõhulahtisus, lööve, stomatiit (suu limaskesta põletik), küünekahjustused, nahakuivus, isutus, konjunktiviit (silmade punetus ja ebamugavustunne silmas), kehakaalu vähenemine, alopeetsia (juuste väljalangemine), sügelus, transaminaaside sisalduse suurenemine (maksaprobleemide sümptom) ja iiveldus.
English: In lung cancer cells, EGFR is often overactive, causing uncontrolled growth of cancer cells.
Estonian: Kopsuvähi rakkudes on EGFR sageli liiga aktiivne, põhjustades vähirakkude kontrollimatut vohamist.
English: In one main study
Estonian: Ühes
English: For more information about using Vizimpro, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Vizimpro kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vizimpro have been included in the summary of product characteristics and the package leaflet.
Estonian: Vizimpro ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: What are the risks associated with Vizimpro?
Estonian: Mis riskid Vizimproga kaasnevad?
English: By blocking EGFR, dacomitinib helps to reduce the growth and spread of the cancer.
Estonian: EGFR-i blokeerides aitab dakomitiniib aeglustada vähi kasvu ja levikut.
English: Vizimpro contains the active substance dacomitinib.
Estonian: Vizimpro sisaldab toimeainena dakomitiniibi.
English: Vizimpro can only be obtained with a prescription and treatment must be started and supervised by a doctor with experience in using cancer medicines.
Estonian: Ravi tohib alustada ning jälgida ainult vähiravimite kasutamises kogenud arst.
English: The most frequent serious side effects are diarrhoea, interstitial lung disease (disorders causing scarring in the lungs), rash and loss of appetite.
Estonian: Kõige sagedamad rasked kõrvalnähud on kõhulahtisus, interstitsiaalne kopsuhaigus (kopsude sidekoestumist põhjustavad häired), lööve ja isutus.
English: For the full list of side effects and restrictions of Vizimpro, see the package leaflet.
Estonian: Vizimpro kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: involving 452 patients with EGFR mutations, patients given Vizimpro lived on average for around 15 months without their disease getting worse, compared with 9 months for those given gefitinib.
Estonian: põhiuuringus, kus osales 452 EGFR-i mutatsioonidega patsienti, oli keskmine progresseerumiseta elumus Vizimprot kasutanud patsientidel ligikaudu 15 kuud ja gefitiniibi kasutanud patsientidel 9 kuud.
English: The active substance in Vizimpro, dacomitinib, belongs to a group of cancer medicine called tyrosine kinase inhibitor.
Estonian: Vizimpro toimeaine dakomitiniib kuulub vähiravimite türosiinkinaasi inhibiitorite rühma.
English: Vizimpro has been shown to be more effective than gefitinib (another medicine for non-small cell lung cancer) at prolonging the time patients lived without their disease getting worse.
Estonian: Vizimpro on osutunud efektiivsemaks kui gefitiniib (samuti mitteväikerakk-kopsuvähi ravim) progresseerumiseta elumuse (kui kaua patsiendid elasid haiguse süvenemiseta) pikendamisel.
English: Vizimpro is a cancer medicine used to treat adults with non-small cell lung cancer (NSCLC) when the disease is advanced or has spread.
Estonian: Vizimpro on vähiravim, mida kasutatakse mitteväikerakk-kopsuvähi ravimiseks täiskasvanutel, kui haigus on kaugelearenenud või levinud organismis mujale.
English: How does Vizimpro work?
Estonian: Kuidas Vizimpro toimib?
English: How is Vizimpro used?
Estonian: Kuidas Vizimprot kasutatakse?
English: Patients taking Vizimpro lived for an extra 6 months without their disease getting worse compared with those taking gefitinib.
Estonian: Vizimprot võtvad patsiendid elasid haiguse süvenemiseta 6 kuud kauem kui gefitiniibi võtvad patsiendid.
English: What benefits of Vizimpro have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Vizimpro kasulikkus?
English: An overview of Vizimpro and why it is authorised in the EU
Estonian: Ülevaade ravimist Vizimpro ja ELis müügiloa väljastamise põhjendus
English: Vizimpro was shown to significantly improve the length of time patients lived without their disease getting worse.
Estonian: Tõendati, et Vizimpro suurendab oluliselt progresseerumiseta elumust.
English: The company submitted the results of two main studies.
Estonian: Ettevõte esitas kahe põhiuuringu tulemused.
English: EMA/177547/2013 EMEA/H/C/002429
Estonian: 21. märts 2013 EMA/275088/2013 EMEA/H/C/002429
English: What is Kynamro?
Estonian: Mis on Kynamro?
English: This was considered an important limitation because Kynamro is intended for long-term treatment.
Estonian: Seda peeti oluliseks piiranguks, sest Kynamro on ette nähtud pikaajaliseks raviks.
English: After considering the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the refusal of the marketing authorisation on 21 March 2013.
Estonian: Pärast taotluse põhjenduste kaalumist vaatas inimravimite komitee oma algse arvamuse uuesti läbi ja kinnitas 21. märtsil 2013 soovist müügiloa andmisest keelduda.
English: During the re-examination in March 2013, the CHMP's concerns remained unresolved and were not fully addressed by measures proposed by the company.
Estonian: Taasläbivaatamise ajal märtsis 2013 ei olnud inimravimite komitee vaatluse all olnud probleemid lahenenud ja ettevõtte välja pakutud meetmed ei katnud neid täielikult.
English: The company that applied for authorisation is Genzyme Europe B.V.
Estonian: Müügiluba taotles Genzyme Europe B.V.
English: Patients applying for compassionate use programmes will continue to be evaluated and will receive the medicine if eligible.
Estonian: Eriloaga kasutamise programme taotlevate patsientide hindamist jätkatakse ja nad saavad ravimit, kui see on õigustatud.
English: By blocking the production of apolipoprotein B, Kynamro was expected to reduce the levels of these types of lipoproteins in the blood of patients.
Estonian: Eeldati, et apolipoproteiin B tootmise blokeerimisega vähendab Kynamro nende lipoproteiinitüüpide sisaldust patsientide veres.
English: Therefore, at that point in time, the CHMP was of the opinion that the benefits of Kynamro did not outweigh its risks and recommended that it be refused marketing authorisation.
Estonian: Seetõttu oli inimravimite komitee sel ajal arvamusel, et Kynamro kasulikkus ei ole suurem kui kaasnevad riskid, ja soovitas müügiloa andmisest keelduda.
English: Refusal of the marketing authorisation for Kynamro (mipomersen) EMA/177547/2013
Estonian: Kynamro (mipomerseen) müügiloa andmisest keeldumine EMA/275088/2013
English: Patients with homozygous familial hypercholesterolaemia have high blood levels of these types of cholesterol, which increases the risk of coronary heart disease (heart disease caused by the obstruction of the blood vessels that supply the heart muscle).
Estonian: Homosügootse familiaalse hüperkolesteroleemiaga patsientidel on nende kolesteroolitüüpide sisaldus veres suur, mis suurendab südame koronaartõve (südamehaigus, mida põhjustab südamelihast verega varustavate veresoonte ummistumine) riski.
English: One involved 51 patients with homozygous familial hypercholesterolaemia and the other involved 58 patients with severe heterozygous familial hypercholesterolaemia.
Estonian: Ühes osales 51 homosügootse familiaalse hüperkolesteroleemiaga patsienti ja teises 58 raske heterosügootse familiaalse hüperkolesteroleemiaga patsienti.
English: Refusal of the marketing authorisation for Kynamro (mipomersen)
Estonian: Kynamro (mipomerseen) müügiloa andmisest keeldumine
English: It was expected to be used together with other cholesterol-lowering medicines and a low-fat diet.
Estonian: Ravimit kavatseti kasutada koos muude kolesteroolisisaldust vähendavate ravimite ja vähese rasvasisaldusega dieediga.
English: The main measure of effectiveness was the reduction in the patients' LDL cholesterol levels.
Estonian: Efektiivsuse põhinäitaja oli patsientide vere LDL-kolesterooli sisalduse vähenemine.
English: This prevented the CHMP from concluding that Kynamro's intended cardiovascular benefit, in terms of reducing cholesterol levels, outweighed its potential cardiovascular risk.
Estonian: Seetõttu ei saanud inimravimite komitee järeldada, et Kynamro eeldatav kardiovaskulaarne kasulikkus kolesteroolisisalduse vähendamise seisukohalt oleks suurem kui selle võimalik kardiovaskulaarne risk.
English: In December 2012, the CHMP was concerned that a high proportion of patients stopped taking the medicine within two years, even in the restricted group of patients with homozygous familial hypercholesterolaemia, mainly due to side effects.
Estonian: 2012. aasta detsembris muutus inimravimite komitee ettevaatlikuks, sest suur osa patsientidest lõpetas peamiselt kõrvaltoimete tõttu ravimi võtmise kahe aasta jooksul, isegi homosügootse familiaalse hüperkolesteroleemiaga patsientide piiratud rühmas.
English: It was to be available as a solution for injection under the skin.
Estonian: Seda kavatseti turustada süstelahusena süstimiseks naha alla.
English: On 13 December 2012, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Kynamro, intended for the treatment of patients with certain forms of familial hypercholesterolaemia.
Estonian: 13. detsembril 2012 võttis inimravimite komitee vastu negatiivse otsuse, soovitades ravimi Kynamro müügiloa andmisest keelduda.
English: How is Kynamro expected to work?
Estonian: Milline on Kynamro eeldatav toime?
English: The studies compared the effects of Kynamro with placebo when added onto treatment with other cholesterol-lowering medicines and a low-fat diet, for a treatment period of 26 weeks.
Estonian: Uuringud võrdlesid 26-nädalase raviperioodi jooksul Kynamro toimet platseeboga, kui ravimit lisati muudele kolesteroolisisaldust vähendavatele ravimitele ja rasvavaesele dieedile.
English: Therefore, the CHMP refusal was confirmed after re-examination.
Estonian: Pärast taasläbivaatamist kinnitas komitee seetõttu oma keeldumist.
English: The effects of Kynamro were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Kynamro toimet muude katsetega.
English: During the assessment of Kynamro, the indication was restricted to the most severely affected patients with homozygous and compound heterozygous familial hypercholesterolaemia only.
Estonian: Kynamro hindamise ajal oli näidustus piiratud ainult homosügootse ja heterosügootse familiaalse hüperkolesteroleemiaga patsientidega, kelle haigus oli eriti raske.
English: Moreover, the Committee was concerned that more cardiovascular events (problems with the heart and blood vessels) were reported in patients taking Kynamro than in patients taking placebo.
Estonian: Komitee oli ettevaatlik ka seetõttu, et Kynamrot võtvatel patsientidel teatati kardiovaskulaarsete (südame-veresoonkonna) häirete esinemisest sagedamini kui platseebot võtvatel patsientidel.
English: It was initially expected to be used to treat two closely related forms of the disease called ‘severe heterozygous' and ‘homozygous' familial hypercholesterolaemia.
Estonian: Kynamrot kavatseti kasutada kahe lähedalt seotud haigusvormi - raske heterosügootse ja homosügootse familiaalse hüperkolesteroleemia - raviks.
English: The CHMP was also concerned by the potential longterm consequences of liver test results showing a build-up of fat in the liver and increased enzyme levels, and was not convinced that the company had proposed sufficient measures to prevent the risk of irreversible liver damage.
Estonian: Inimravimite komitee oli samuti ettevaatlik maksatestide tulemuste võimalike pikaajaliste tagajärgede pärast, mis näitasid rasva kogunemist maksa ja suurenenud ensüümisisaldust.
English: Kynamro is a medicine that contains the active substance mipomersen.
Estonian: Kynamro toimeaine on mipomerseen.
English: The active substance in Kynamro, mipomersen, is an ‘antisense oligonucleotide', a very short fragment of DNA designed to block the production of a protein called apolipoprotein B, by attaching to the genetic material of cells responsible for producing it. Apolipoprotein B is the main component of ‘low density lipoprotein' (LDL) cholesterol, commonly known as ‘bad cholesterol', and of two closely related types of cholesterol called ‘intermediate density lipoprotein' (IDL) and ‘very low density lipoprotein' (VLDL) cholesterol.
Estonian: Apolipoproteiin B on LDL-kolesterooli (mida nimetatakse tavaliselt nn halvaks kolesterooliks) ja kahe sellega lähedalt seotud kolesteroolitüübi IDL-kolesterooli ja VLDL-kolesterooli peamine koostisosa.
English: Kynamro was expected to be used to treat patients with an inherited disease causing high blood cholesterol levels, called familial hypercholesterolaemia.
Estonian: Kynamrot kavatseti kasutada vere suurt kolesteroolisisaldust põhjustava, familiaalseks hüperkolesteroleemiaks nimetatava päriliku haigusega patsientide raviks.
English: What was Kynamro expected to be used for?
Estonian: Milleks kavatseti Kynamrot kasutada?
English: Strength Pharmaceutical
Estonian: Tugevus Ravimvorm Loomaliigid ManustamisviisPakend
English: - if you have ever had tuberculosis or if you have been in close contact with someone who has or has had tuberculosis.
Estonian: • kui olete kunagi põdenud tuberkuloosi või olete olnud kontaktis inimesega, kellel on või on olnud tuberkuloos.
English: Not applicable.
Estonian: Ei kohalda.
English: A more than 3-fold increase was seen in another 5 patients.
Estonian: Enam kui 3kordset tõusu täheldati veel 5 patsiendil.
English: Your doctor may perform tests to see if you have tuberculosis.
Estonian: Teie arst võib määrata uuringud, et teha kindlaks, kas teil on tuberkuloos;
English: 3°years
Estonian: 3 aastat
English: However there was a wide variability in final outcome, i.e. in some patients the neuropathy resolved and some patients had persistent symptoms.
Estonian: Lõpptulemused varieerusid siiski suuresti, st mõnedel patsientidel neuropaatia taandus ja mõnedel patsientidel sümptomid püsisid.
English: UAB "Sicor Biotech" filiāle Latvijā
Estonian: Latvija UAB "Sicor Biotech" filiāle Latvijā
English: Date of first authorisation: 29 November 2010 Date of latest renewal: 19 June 2015
Estonian: Müügiloa viimase uuendamise kuupäev: 19. juunil 2015
English: Do not use this medicine after the expiry date which is stated on the outer carton and on the bottle after EXP.
Estonian: Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud välispakendil pärast EXP ja pudelil pärast Kõlblik kuni.
English: Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Estonian: Teatage oma arstile või apteekrile, kui te võtate, olete hiljuti võtnud või kavatsete võtta mistahes muid ravimeid, kaasa arvatud käsimüügiravimid.
English: Do not take Leflunomide ratiopharm if you are, or think you may be pregnant.
Estonian: Ärge võtke Leflunomide ratiopharmi kui olete või arvate ennast olevat rase.
English: Leflunomide ratiopharm is not recommended for use in patients below 18 years since efficacy and safety in juvenile rheumatoid arthritis (JRA) have not been established (see sections 5.1 and 5.2).
Estonian: Leflunomide ratiopharmi ei soovitata alla 18-aastaste patsientide raviks, sest efektiivsust ja ohutust juveniilse reumatoidartriidi (JRA) korral ei ole kindlaks tehtud (vt lõigud 5.1 ja 5.2).
English: This may be reduced to a few weeks by taking certain medicines which speed up removal of Leflunomide ratiopharm from your body.
Estonian: Seda perioodi saab lühendada mõne nädalani, võttes teatud ravimeid, mis kiirendavad Leflunomide ratiopharmi väljutamist teie organismist.
English: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Estonian: Väga sage (1/10); sage (1/100 kuni <1/10); aeg-ajalt (1/1000 kuni <1/100); harv (1/10000 kuni <1/1000); väga harv (<1/10000), teadmata (ei saa hinnata olemasolevate andmete alusel).
English: Your doctor will also check your blood pressure regularly as Leflunomide ratiopharm can cause an increase in blood pressure.
Estonian: Samuti tuleb regulaarselt teie vererõhku kontrollida, sest Leflunomide ratiopharm võib põhjustada vererõhu tõusu.
English: The initial period was followed by an open label maintenance period of three months, during which both groups received leflunomide 20 mg daily.
Estonian: Algsele perioodile järgnes kolmekuuline avatud säilitusravi periood, mille käigus mõlemas rühmas manustati 20 mg leflunomiidi päevas.
English: Take the tablet with plenty of water.
Estonian: Võtke tablett rohke veega.
English: severe infections, including sepsis which may be fatal
Estonian: tõsised infektsioonid, kaasa arvatud sepsis, mis võib osutuda fataalseks.
English: There have been reports of chronic overdose in patients taking Leflunomide ratiopharm at daily doses up to five times the recommended daily dose, and reports of acute overdose in adults and children.
Estonian: Teatatud on kroonilistest üleannustamistest patsientidel, kes võtsid Leflunomide ratiopharmi soovitavast päevaannusest kuni viis korda suuremates annustes ning ägedast üleannustamisest täiskasvanutel ja lastel.
English: This metabolite is responsible for essentially all the in-vivo activity of Leflunomide ratiopharm.
Estonian: See metaboliit on aluseks praktiliselt kogu Leflunomide ratiopharmi toimele in vivo.
English: Men wishing to father a child should contact their doctor who may advise them to stop taking Leflunomide ratiopharm and take certain medicines to remove Leflunomide ratiopharm rapidly and sufficiently from their body.
Estonian: Mehed, kes soovivad isaks saada, peavad ühendust võtma oma arstiga, kes võib neile soovitada Leflunomide ratiopharmi kasutamise lõpetamist ning teatud ravimite võtmist, mis väljutavad Leflunomide ratiopharmi kiiresti ja piisavalt nende organismist.
English: Leflunomide ratiopharm is not recommended for use in children and adolescents below 18 years of age.
Estonian: Lapsed ja noorukid Leflunomide ratiopharm ei ole näidustatud kasutamiseks lastel ja alla 18 a noorukitel.
English: If you are pregnant or become pregnant while taking Leflunomide ratiopharm, the risk of having a baby with serious birth defects is increased.
Estonian: Kui te olete rase või rasestute Leflunomide ratiopharmi võtmise ajal, on lapsel tõsiste sünnidefektide suurenenud tekkerisk.
English: The efficacy of Leflunomide ratiopharm in the treatment of rheumatoid arthritis was demonstrated in 4 controlled trials (1 in phase II and 3 in phase III).
Estonian: Leflunomide ratiopharmi efektiivsust reumatoidartriidi ravis demonstreeriti neljas kontrollrühmaga (ühes II faasi ning kolmes III faasi) uuringus.
English: What Leflunomide ratiopharm is and what it is used for What you need to know before you take Leflunomide ratiopharm How to take Leflunomide ratiopharm Possible side effects
Estonian: Mis ravim on Leflunomide ratiopharm ja milleks seda kasutatakse Mida on vaja teada enne Leflunomide ratiopharmi võtmist Kuidas Leflunomide ratiopharmi võtta Võimalikud kõrvaltoimed
English: The information provided in the Physician Leaflet should provide information on dose reduction, discontinuation and wash out procedures in the event of raised ALT.
Estonian: Infoleht arstile peab sisaldama teavet annuse vähendamise, katkestamise ja puhastusprotseduuride kohta ALATi suurenemise korral.
English: If the test confirms that you are pregnant, your doctor may suggest treatment with certain medicines to remove Leflunomide ratiopharm rapidly and sufficiently from your body, as this may decrease the risk to your baby.
Estonian: Kui testid teie rasedust kinnitavad, võib arst teile soovitada ravi teatud ravimitega, mis väljutavad Leflunomide ratiopharmi kiiresti ja piisavalt teie organismist ning see võib vähendada riski lapsele.
English: Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Estonian: HANKE- JA KASUTUSTINGIMUSED VÕI -PIIRANGUD Piiratud tingimustel väljastatav retseptiravim (vt I lisa: Ravimi omaduste kokkuvõte, lõik 4.2).
English: Leflunomide ratiopharm can make you feel dizzy which may impair your ability to concentrate and react.
Estonian: Leflunomide ratiopharm võib põhjustada peapööritust, see võib häirida teie keskendumisvõimet ja reaktsioonikiirust.